All posts by: Michael Zand

About Michael Zand

President* Trump vs. His Environment – Esquire.com

Continue reading

2017-02-16 NEWS

Esquire.com

President* Trump vs. His Environment
Esquire.com
I wish there was something funny I could write about what’s going to happen to the Environmental Protection Agency once the Senate approves the absurd nomination of Scott Pruitt to head an agency that he is at the moment suing on behalf of the state of …

and more »

Continue reading

2017-02-16 NEWS

Phys.Org

Modifying fat content in soybean oil with the molecular scissors Cpf1
Phys.Org
CRISPRCpf1 is introduced into plant cells without cell walls (protoplasts) as a pre-assembled complex of the protein Cpf1 (red scissors) and the CRISPR-RNA (crRNA, in blue). Cpf1 functions as gene scissors that cuts the plant’s DNA (shown …more.
Scientists use CRISPRCpf1 technology to modify fat in soybean oildomain-B

all 51 news articles »

Continue reading

2017-02-16 NEWS

Intellectual Property Watch

New Gene-Editing Technology Whets Appetites In Health, Food Industry, Fuels Patent Fights
Intellectual Property Watch
In January, Monsanto announced it had reached “a new global licensing agreement with the Broad Institute of MIT and Harvard for the use of the novel CRISPRCpf1 genome-editing technology in agriculture.” CRISPRCpf1, according to the release, “is an …

Continue reading

2017-02-16 NEWS

Immuno-Oncology News

Immunotherapy Combo Trial for Advanced Solid Tumors Doses First Patient
Immuno-Oncology News
A Phase 1 trial assessing a combination of the immune checkpoint inhibitor Yervoy (ipilimumab) and Transgene’s oncolytic virus Pexa-Vec as a treatment for multiple advanced solid tumors has dosed its first patient at the Léon Bérard Cancer Center in

Continue reading

2017-02-16 NEWS

Lonza to Manufacture Selecta Gene Therapy Candidate for MMA
Genetic Engineering & Biotechnology News
Lonza’s viral-based therapeutics unit Lonza Houston has agreed to manufacture an Anc80-AAV–based gene therapy product for Selecta Bioscience’s proprietary program for the treatment of methylmalonic acidemia (MMA) and may produce other …
Lonza and Selecta Biosciences (SELB) Announce Manufacturing Agreement for Anc80-AAV-Based Gene TherapyStreetInsider.com

all 3 news articles »

Continue reading

2017-02-16 NEWS

Genetic Engineering & Biotechnology News

Rare Muscle Disease Treated Successfully with Gene Therapy
Genetic Engineering & Biotechnology News
Work on gene therapy is showing significant progress for restoring muscle strength and prolonging lives in dogs with a previously incurable, inherited neuromuscular disease, according to scientists at the University of Washington Medicine Institute for
Regenerative Medicine Market Growing at a CAGR of 23.6 % During 2016 to 2021PR Newswire India (press release)

all 15 news articles »